drugset / Trial / NCT02686216

Biodistribution, Pharmacokinetics, and Safety of F-18 THK-5351 PET in Alzheimer's Disease Patients and Healthy Subjects.(Positron Emission Tomograph )

NCT02686216 ↗

Phase 1 Completed 24 enrolled Chang Gung Memorial Hospital
NaSingle-groupOpen-labelDiagnostic

Summary

Biodistribution, pharmacokinetics, and safety of F-18 THK-5351 PET in Alzheimer's disease patients and healthy subjects.

Timeline

Start
2015-12
Primary completion
2016-04
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject F-18 THK-5351 Diagnostic / imaging agent 370 mbq —

Indications